HC Wainwright & Co. Maintains Buy on Regulus Therapeutics, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Regulus Therapeutics (NASDAQ:RGLS) and raised the price target from $9 to $10.
June 25, 2024 | 10:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on Regulus Therapeutics and raised the price target from $9 to $10.
The Buy rating and increased price target from a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and drive short-term price appreciation for Regulus Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100